https://www.taxtmi.com/article/detailed?id=6854 The document emphasises a liberalised FDI regime allowing full foreign equity in pharmaceutical manufacturing (Greenfield and Brownfield subject to Brownfield conditions), accompanied by certification requirements disallowing non compete clauses in inter se agreements; it highlights government incentives (tax breaks, weighted R&D deductions, venture funds, biotech parks), regulatory oversight by central drug authorities and the NPPA for pricing control, and the shift to product patents post 2005, all of which shape investment, R&D strategy and compliance obligations in the industry. en-us Sat, 11 Jun 2016 11:33:52 +0530 Sat, 11 Jun 2016 11:33:52 +0530 TaxTMI RSS Generator https://www.taxtmi.com/article/detailed?id=6854 The document emphasises a liberalised FDI regime allowing full foreign equity in pharmaceutical manufacturing (Greenfield and Brownfield subject to Brownfield conditions), accompanied by certification requirements disallowing non compete clauses in inter se agreements; it highlights government incentives (tax breaks, weighted R&D deductions, venture funds, biotech parks), regulatory oversight by central drug authorities and the NPPA for pricing control, and the shift to product patents post 2005, all of which shape investment, R&D strategy and compliance obligations in the industry. Articles Other Topics Sat, 11 Jun 2016 11:33:52 +0530 https://www.taxtmi.com/article/detailed?id=6854